MEDICAL INQUIRIES MEDICAL INQUIRIES

THERAPEUTIC AREAS THERAPEUTIC AREAS

DISEASE AWARENESS DISEASE AWARENESS

DRUG PORTFOLIO DRUG PORTFOLIO

CONGRESSES AND PUBLICATIONS CONGRESSES AND PUBLICATIONS

Contact Us

Call 1-888-275-7376
(8-5:30 ET M-F)

Submit Med Info Request

Adverse Event:
1-800-283-8088, ext. 5563

eMedI Chat: Medical Information Database

Please click the eMedI Chat icon in the lower right corner of your screen to use our chatbot and search the Medical Information database

Temperature Stability Calculator

Have a question about a temperature excursion?

Therapeutic Areas

Discover our resource library on diseases, products, congresses, publications, and more, organized by therapeutic areas

Disease Awareness

Find information on disease areas of interest

Marketed Products

Find information on our marketed products

Pipeline Agents

Find information on our pipeline agents

Congress Presentations

Explore our library of congress presentations

Journal Publications

Discover our library of select journal publications

eMedI Chat

ASCO 2022

American Society of Clinical Oncology (ASCO) 2022 - June 3-7, 2022 / Chicago, IL and Virtual

Search results containing information about pipeline products (current or former) or investigational uses of products do not imply Food and Drug Administration (FDA) approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. There is no guarantee that the pipeline products or investigational uses will receive FDA approval. EMD Serono, Inc. does not recommend or suggest use of its products in a manner inconsistent with FDA-approved labeling.

Long-term Outcomes in Patients with Advanced Urothelial Carcinoma who Received Avelumab First-line Maintenance with or without Second-line Treatment: Exploratory Analyses from JAVELIN Bladder 100 (includes plain language summary)

Bellmunt | Poster #4560

Tepotinib in Asian Patients with Advanced NSCLC with MET Exon 14 (METex14) Skipping

Kato | Poster #9120

Clinical Response to Tepotinib According to Circulating Tumor DNA Biomarkers in Patients with Advanced NSCLC with High-level MET Amplification Detected by Liquid Biopsy

Le | Poster #9121

Evaluating Oncologists’ Practice Patterns and Decision-Making in Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC): the US Physician PARADIGM Study (part 2)

Liu | Poster #4595

Phase 1 Trial of First-line Bintrafusp alfa in Combination with Other Anticancer Therapies in Patients with Locally Advanced or Advanced Cervical Cancer

Oaknin | Poster #5528

Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Outcomes from JAVELIN Bladder 100 in Subgroups Defined by Response to First-line Chemotherapy (includes plain language summary)

Valderrama | Poster #4559

This site is intended for US healthcare professionals only.

DISCLAIMER: This site contains medical information that is intended for healthcare providers of the United States only. The medical information contained on this site is not meant to substitute for the advice provided by a medical professional. Canadian residents should consult the EMD Serono Canada Inc. website at www.emdserono.ca for information on products and services approved in Canada. Use and access of this site is subject to the terms and conditions as set out in our Legal Statement and Privacy Policy.

EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany, in the United States and Canada.

US-MULNP-00023 09/24

By clicking this link, you are leaving medical.emdserono.com. Please, note that this link will take you to a website on which different Privacy Policy and Conditions may apply. EMD Serono accepts no responsibility for websites not controlled directly by us. Please check Privacy Policy and Conditions of the linked website.

Welcome to EMD Serono Medical Information!

Help us direct you to the right information by selecting one of the following options: